P26007 Pre-Assessment – Medical Learning Institute Inc

Pre-Assessment

Name

First

Last

Email

NPI Number:

Location

Which of the following best represents your profession?

MD/DO
NP
PA
Other (please specify below)

If other please specify:

What is your primary specialty?

Family Medicine
Primary Care
Internal Medicine
Other (please specify below)

If other please specify:

1. Which of the following statements is TRUE regarding once-weekly basal insulin when compared to once-daily basal insulin?

a. Has the ability to more closely mimic endogenous basal insulin distribution profiles
b. Has the ability to rapidly adapt to changes in insulin requirements
c. Has a significantly higher risk for weight gain
d. Has a significantly higher risk for severe hypoglycemia

Please select the extent to which you feel confident in your answer

Completely confident	Fairly confident	Somewhat confident	Slightly confident	Not confident
Completely confidentItem #1 Completely confident	Fairly confidentItem #1 Fairly confident	Somewhat confidentItem #1 Somewhat confident	Slightly confidentItem #1 Slightly confident	Not confidentItem #1 Not confident

2. A 58-year-old man with Type 2 diabetes (T2D) has an A1C of 8.6% despite maximally tolerated oral therapy. He works irregular shifts, frequently misses daily medications, and expresses concern about managing insulin injections and dose adjustments. Which of the following attributes of emerging once-weekly basal insulin might influence its use over traditional once-daily basal insulin for this patient?

a. Achieves higher glycemia control
b. Reaches peak insulin levels faster
c. Promotes glucose-dependent insulin release
d. Has slower clearance and extended half-life

Please select the extent to which you feel confident in your answer

Completely confident	Fairly confident	Somewhat confident	Slightly confident	Not confident
Completely confidentItem #1 Completely confident	Fairly confidentItem #1 Fairly confident	Somewhat confidentItem #1 Somewhat confident	Slightly confidentItem #1 Slightly confident	Not confidentItem #1 Not confident

3. What was noted regarding reduction in HbA1C with once-weekly insulin efsitora alfa versus once-daily insulin therapy in patients with T2D in the QWINT clinical trials program?

a. Statistically superior in insulin-naïve patients
b. Statistically non-inferior in insulin-naïve patients
c. Statistically inferior in insulin-naïve patients
d. Statistically superior in insulin-pretreated patients

Please select the extent to which you feel confident in your answer

Completely confident	Fairly confident	Somewhat confident	Slightly confident	Not confident
Completely confidentItem #1 Completely confident	Fairly confidentItem #1 Fairly confident	Somewhat confidentItem #1 Somewhat confident	Slightly confidentItem #1 Slightly confident	Not confidentItem #1 Not confident

4. Based on the results from the ONWARDS clinical trials program, how would you counsel your patient with T2D to manage expectations regarding the incidence of severe hypoglycemic events with once-weekly insulin icodec compared with that of once-daily basal insulin therapy?

a. Severe hypoglycemic events are likely to be significantly higher
b. Severe hypoglycemic events are likely to be significantly lower
c. Severe hypoglycemia events are likely to be comparable
d. No severe hypoglycemia events are expected

Please select the extent to which you feel confident in your answer

Completely confident	Fairly confident	Somewhat confident	Slightly confident	Not confident
Completely confidentItem #1 Completely confident	Fairly confidentItem #1 Fairly confident	Somewhat confidentItem #1 Somewhat confident	Slightly confidentItem #1 Slightly confident	Not confidentItem #1 Not confident

5. For which of the following patient types with T2D who require basal insulin therapy would you most likely recommend a once-weekly formulation, if it were available for routine use?

a. A younger patient who is wary of weight gain
b. An older patient with cognitive or physical limitations
c. A patient who wants to avoid episodes of severe hypoglycemia
d. A patient who is fearful of injections

Please select the extent to which you feel confident in your answer

Completely confident	Fairly confident	Somewhat confident	Slightly confident	Not confident
Completely confidentItem #1 Completely confident	Fairly confidentItem #1 Fairly confident	Somewhat confidentItem #1 Somewhat confident	Slightly confidentItem #1 Slightly confident	Not confidentItem #1 Not confident

6. When using a continuous glucose monitor (CGM) for titration of basal insulin in patients with T2D, which of the glucose measurements should be used to adjust basal insulin?

a. Mean glucose readings over 24 hours
b. Fasting blood glucose and lowest glucose value of the day
c. Postprandial glucose after the largest daily meal
d. Daytime glucose variability, including fluctuations related to physical activity

HbA1C answer routine

Please select the extent to which you feel confident in your answer

Completely confident	Fairly confident	Somewhat confident	Slightly confident	Not confident
Completely confidentItem #1 Completely confident	Fairly confidentItem #1 Fairly confident	Somewhat confidentItem #1 Somewhat confident	Slightly confidentItem #1 Slightly confident	Not confidentItem #1 Not confident

7. How confident are you in your ability to initiate once-weekly basal insulin, if it becomes available, for patients with T2D?